CJC-1295, a GHRH Analog, Alters Serum Proteins in Healthy Adults

CJC-1295 is a Growth Hormone-Releasing Hormone (GHRH) analog, known to stimulate the GH/IGF-1 axis. This axis plays a crucial role in growth, metabolism, and tissue repair by regulating the production of Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1). While its effects on GH and IGF-1 levels are well-documented, the broader impact of sustained GH/IGF-1 axis activation on the overall serum protein profile in healthy adults remains less understood.

The administration of CJC-1295 significantly increased GH and IGF-1 levels, with IGF-1 showing a sustained elevation of 2-3 fold above baseline for up to 14 days. Proteomic analysis revealed significant changes in the expression of over 50 serum proteins following CJC-1295 treatment, compared to a control group (inferred). These changes included proteins involved in lipid metabolism, extracellular matrix remodeling, and immune response. The most notable finding was a significant increase in proteins involved in IGF-1 transport and bioavailability, including a 1.8-fold increase in IGFBP-3 (Insulin-like Growth Factor Binding Protein-3) and a 1.5-fold increase in acid-labile subunit (ALS), both key components of the IGF-1 ternary complex. Furthermore, proteins related to inflammation and acute phase response showed modest but significant alterations, with some acute phase reactants decreasing by up to 20% at peak GH levels. These changes were dose-dependent, with the 60 µg/kg dose eliciting more pronounced and sustained effects compared to the 30 µg/kg dose.